Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2010 Results
Date:2/10/2011

)-0.1%Net Revenues64,908102.2%57,86798.6%Cost of Goods Sold44,57870.2%43,35373.9%Gross Profit20,33032.0%14,51424.7%Operating ExpensesSelling, General and Administrative Expenses9,24014.5%8,82215.0%Research and Development Expenses2,3993.8%2,0053.4%Restructuring Expenses1060.2%-0.0%Merger and Acquisition Expenses2110.3%-0.0%Total Operating Expenses11,95618.8%10,82718.4%Operating Profit8,37413.2%3,6876.3%Other Expenses/(Income):Interest Expense, net7891.2%1,2242.1%Other Expense/(Income), net5270.8%(502)-0.9%Equity in Losses of Partially-Owned Affiliate2860.5%-0.0%Income Before Income Taxes6,77210.7%2,9655.1%Provision for Income Taxes1,5282.4%5,7339.8%Income/(Loss) from Continuing Operations

$

5,2448.3%$

(2,768)-4.7%Loss from Discontinued Operations(597)-1.0%-0.0%Net Income/(Loss)

$

4,6477.3%$

(2,768)-4.7%Basic Earnings/(Loss) per Share of Common Stock:   Income/(Loss) from Continuing Operations

$

0.18$

(0.09)   Loss from Discontinued Operations

$

(0.02)$

-  Net Income/(Loss)

$

0.16$

(0.09)Diluted Earnings/(Loss) per Share of Common Stock:   Income/(Loss) from Continuing Operations

$

0.18$

(0.09)   Loss from Discontinued Operations

$

(0.02)$

-  Net Income/(Loss)

$

0.16$

(0.09)Weighted Average Shares OutstandingBasic29,42029,286Diluted29,48929,286CAMBREX CORPORATIONStatements of Profit and LossFor the Twelve Months Ended December 31, 2010 and 2009(in thousands)20102009% of% ofAmountSalesAmountSalesGross Sales

$

226,436100.0%$

236,277100.0%Commissions, Allowances and Rebates1,5450.7%1,4020.6%Net Sales224,89199.3%234,87599.4%Other Revenues2,1010.9%(325)-0.1%Net Revenues226,992100.2%234,55099.3%Cost of Goods Sold160,12670.7%164,27269.6%Gross Profit66,86629.5%70,27829.7%Operating ExpensesSelling, General and Administrative Expenses34,02415.0%35,71115.1%Resear
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
2. Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009
3. Cambrex Reports Third Quarter 2009 Results
4. Cambrex Acquires IEP GmbH
5. Cambrex to Announce Third Quarter 2010 Financial Results on November 3, 2010
6. Cambrex Acquires Stake in Zenara Pharma
7. Cambrex Zenara Supplies Product for Launch of Nicorette® in India
8. Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
9. Cambrex Zenara Manufacturing Facility Receives European GMP Approval
10. Cambrex to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Elekta (NSE:EKTAb) and Royal ... Christie NHS Foundation Trust ( Manchester, UK ... whose mission is to develop the clinical value of ... system. Such a system would, in principle, improve the ... "The Christie was an essential participant ...
(Date:7/22/2014)... SAN DIEGO , July 22, 2014  Halozyme ... that it has resumed enrollment and dosing of patients ... PEGPH20 in patients with pancreatic cancer under the revised ... PEGPH20 is an investigational PEGylated form of Halozyme,s proprietary ... of tumors that accumulate hyaluronan. "Our ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... N.J., Nov. 4 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... months ended September 30, 2009, ending the quarter with $67.5 ... million from December 31, 2008. In October 2009, we ... offering costs from an underwritten public offering of 4,945,000 shares ...
... , PARIS, Nov. 4 Alcatel-Lucent (Euronext Paris and ... TeleHealth Manager, a secure and reliable remote patient monitoring ... Drug Administration (FDA) for marketing in the United States. ... supports remote patient monitoring with an easily deployable ...
Cached Medicine Technology:Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 12Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 13Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 14U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 2U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States 3
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... 22, 2014 Alliance Storage ... data archiving solutions, has announced the availability of ... archiving solution. The unique new solution merges optical ... on compliant data archiving across all industries including ... The introduction of the new archiving tier permits ...
(Date:7/22/2014)... Murcia have studied the changes in the brain ... that causes difficulties in inhibiting a response in ... unplanned actions without considering the negative consequences. These ... the risk of behavioural problems. , A new ... Murcia analyses whether the connectivity of an infant,s ...
(Date:7/22/2014)... 22, 2014 There’s an old adage ... to the new improvements and enhancements Global Eyeglasses has ... to make lasting impressions while having what they need ... great, everyday. , “We are offering new sports clip ... said Arjun Sagar, CEO of Global Eyeglasses . ...
(Date:7/22/2014)... As part of a multinational, collaborative effort, ... Sinai have helped identify over 100 locations in the ... in the largest genomic study published on any psychiatric ... published online in Nature, point to biological mechanisms and ... new approaches to treating the disorder, which has seen ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Children's impulsive behaviour is related to their brain connectivity 2Health News:Global Eyeglasses Adds New Products and Enhances Services 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4
... there, experts warn , SUNDAY, Sept. 16 (HealthDay News) ... States occur at home but are preventable, according to ... From cleaning products to coat hangers, the average American ... accidents. Americans can take simple steps, such as wearing ...
... Lifestyle Experts - Plus TV Style, Expert ... Patients Through Live ... 15 People suffering from painful and,at times, embarrassing, ... Foundation officially launched the 2007 PATH program,-- Psoriatic Arthritis ...
... trouble, experts say , , SATURDAY, Sept. 15 (HealthDay News) -- ... or severe stomach pain is another matter that could signal ... People with the following symptoms need to see a doctor: ... pain lasting for hours or days; , pain that wakes ...
... 14 Aid provided by,The Prem Rawat Foundation has ... and their families who were victims of the flooding,earlier ... the flooding, caused by cyclones in this area last ... from their homes. The,Prem Rawat Foundation made a grant ...
... Ill., Sept. 14 The Board of,Directors of ... distributor and,supplier of disposable gloves and other products ... announced it would file a,Form 15 on or ... Exchange,Commission to deregister the Company,s common stock and ...
... HOUSTON, Sept. 14 The following is a,Statement by Oscar S. Wyatt, Jr.: "I,ve seen ... any politicians who want to,return those funds received from me, please return them in the form ... ... DeBakey Medical Foundation ...
Cached Medicine News:Health News:Eye Safety Begins at Home 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 3Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange 2
The only daily cleaner specially formulated with isopropyl alcohol to help dissolve lipids and oil-based make-up from contact lenses....
Clerz Plus helps retain moisture to relieve dryness and removes protein buildup from your lenses while you wear them for longer wear comfort....
Lens Plus rewetting drops for soft contact lenses....
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
Medicine Products: